Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377012586> ?p ?o ?g. }
- W4377012586 endingPage "999" @default.
- W4377012586 startingPage "991" @default.
- W4377012586 abstract "Involvement of lower gastrointestinal tract (LGI) occurs in 60% of patients with graft-versus-host-disease (GVHD). Complement components C3 and C5 are involved in GVHD pathogenesis. In this phase 2a study, we evaluated the safety and efficacy of ALXN1007, a monoclonal antibody against C5a, in patients with newly diagnosed LGI acute GVHD receiving concomitant corticosteroid. Twenty-five patients were enrolled; one was excluded from the efficacy analysis based upon negative biopsy. Most patients (16/25, 64%) had acute leukemia; 52% (13/25) had an HLA-matched unrelated donor; and 68% (17/25) received myeloablative conditioning. Half the patients (12/24) had a high biomarker profile, Ann Arbor score 3; 42% (10/24) had high-risk GVHD per Minnesota classification. Day-28 overall response was 58% (13/24 complete response, 1/24 partial response), and 63% by Day-56 (all complete responses). Day-28 overall response was 50% (5/10) in Minnesota high-risk and 42% (5/12) in high-risk Ann Arbor patients, increasing to 58% (7/12) by Day-56. Non-relapse mortality at 6-months was 24% (95% CI 11–53). The most common treatment-related adverse event was infection (6/25, 24%). Neither baseline complement levels (except for C5), activity, nor inhibition of C5a with ALXN1007 correlated with GVHD severity or responses. Further studies are needed to evaluate the role of complement inhibition in GVHD treatment." @default.
- W4377012586 created "2023-05-19" @default.
- W4377012586 creator A5001900852 @default.
- W4377012586 creator A5005086749 @default.
- W4377012586 creator A5010187992 @default.
- W4377012586 creator A5012691135 @default.
- W4377012586 creator A5019979915 @default.
- W4377012586 creator A5022894871 @default.
- W4377012586 creator A5025530766 @default.
- W4377012586 creator A5034104852 @default.
- W4377012586 creator A5035807701 @default.
- W4377012586 creator A5036412023 @default.
- W4377012586 creator A5039491957 @default.
- W4377012586 creator A5048913229 @default.
- W4377012586 creator A5055885795 @default.
- W4377012586 creator A5070193149 @default.
- W4377012586 creator A5085241715 @default.
- W4377012586 date "2023-05-18" @default.
- W4377012586 modified "2023-10-14" @default.
- W4377012586 title "A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement" @default.
- W4377012586 cites W1491993932 @default.
- W4377012586 cites W1499473785 @default.
- W4377012586 cites W1500757144 @default.
- W4377012586 cites W1516284454 @default.
- W4377012586 cites W1565126658 @default.
- W4377012586 cites W1589464081 @default.
- W4377012586 cites W1599864954 @default.
- W4377012586 cites W1676794103 @default.
- W4377012586 cites W1972665743 @default.
- W4377012586 cites W1977384601 @default.
- W4377012586 cites W1978635205 @default.
- W4377012586 cites W1983187083 @default.
- W4377012586 cites W1999557292 @default.
- W4377012586 cites W2000487018 @default.
- W4377012586 cites W2002353148 @default.
- W4377012586 cites W2010701203 @default.
- W4377012586 cites W2012940838 @default.
- W4377012586 cites W2014981269 @default.
- W4377012586 cites W2023068069 @default.
- W4377012586 cites W2030915050 @default.
- W4377012586 cites W2037163385 @default.
- W4377012586 cites W2046465273 @default.
- W4377012586 cites W2048892546 @default.
- W4377012586 cites W2050602517 @default.
- W4377012586 cites W2051146400 @default.
- W4377012586 cites W2055014838 @default.
- W4377012586 cites W2058963825 @default.
- W4377012586 cites W2060336321 @default.
- W4377012586 cites W2062069007 @default.
- W4377012586 cites W2063271953 @default.
- W4377012586 cites W2065197520 @default.
- W4377012586 cites W2067092037 @default.
- W4377012586 cites W2067803606 @default.
- W4377012586 cites W2069288346 @default.
- W4377012586 cites W2084644134 @default.
- W4377012586 cites W2090123172 @default.
- W4377012586 cites W2097802875 @default.
- W4377012586 cites W2103755206 @default.
- W4377012586 cites W2105179089 @default.
- W4377012586 cites W2113969422 @default.
- W4377012586 cites W2124165032 @default.
- W4377012586 cites W2126622088 @default.
- W4377012586 cites W2139620102 @default.
- W4377012586 cites W2140689375 @default.
- W4377012586 cites W2152757679 @default.
- W4377012586 cites W2157147843 @default.
- W4377012586 cites W2284139314 @default.
- W4377012586 cites W2321365245 @default.
- W4377012586 cites W2339184887 @default.
- W4377012586 cites W2379274574 @default.
- W4377012586 cites W2595675705 @default.
- W4377012586 cites W2621931776 @default.
- W4377012586 cites W285098807 @default.
- W4377012586 cites W2885456062 @default.
- W4377012586 cites W2903648657 @default.
- W4377012586 cites W2979435599 @default.
- W4377012586 cites W2980096072 @default.
- W4377012586 cites W3083382067 @default.
- W4377012586 cites W4236572065 @default.
- W4377012586 cites W4327494057 @default.
- W4377012586 doi "https://doi.org/10.1038/s41409-023-01996-4" @default.
- W4377012586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37202544" @default.
- W4377012586 hasPublicationYear "2023" @default.
- W4377012586 type Work @default.
- W4377012586 citedByCount "1" @default.
- W4377012586 countsByYear W43770125862023 @default.
- W4377012586 crossrefType "journal-article" @default.
- W4377012586 hasAuthorship W4377012586A5001900852 @default.
- W4377012586 hasAuthorship W4377012586A5005086749 @default.
- W4377012586 hasAuthorship W4377012586A5010187992 @default.
- W4377012586 hasAuthorship W4377012586A5012691135 @default.
- W4377012586 hasAuthorship W4377012586A5019979915 @default.
- W4377012586 hasAuthorship W4377012586A5022894871 @default.
- W4377012586 hasAuthorship W4377012586A5025530766 @default.
- W4377012586 hasAuthorship W4377012586A5034104852 @default.
- W4377012586 hasAuthorship W4377012586A5035807701 @default.
- W4377012586 hasAuthorship W4377012586A5036412023 @default.
- W4377012586 hasAuthorship W4377012586A5039491957 @default.